Sequencing to a significant depth using high-sensitivity polymerase chain reaction techniques can uncover low allele fractions and help identify AA cases harboring sub-clonal mutations associated with MDS and AML. 7 The mean allele burdens in AA are substantially lower, at around 10%, when compared to MDS. 4 Recent data from a 
| INTRODUC TI ON
Acquired aplastic anemia (AA) is characterized by a hypoplastic marrow and bone marrow failure, leading to decreased peripheral blood counts. 1 Application of next-generation sequencing (NGS) has allowed for a comprehensive genetic characterization of AA and suggested a paradigm shift in AA pathophysiology from solely immune-mediated bone marrow (BM) hematopoietic stem cells (HSCs) suppression, to include a clonal entity characterized by recurrent somatic mutations (SMs) reminiscent of myeloid malignancies. Specific mutations have been associated with differing clinical outcomes such as their impact on response to immunosuppressive therapy (IST), progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and survival. [2] [3] [4] Their clinical significance is seemingly informed by the specific gene 4 and nature of the mutation involved, 5 clonal size dynamics (mutational allele burden), 6 mutational hierarchy (ie, somatic ancestral events vs sub-clonal events), 5 and variant allelic fraction progression over time. 4, 6 These mutations mark clonally derived populations in a HSC mosaicism, and serve as valuable markers for monitoring clonal dynamics of the stem cell compartment and in predicting MDS/AML evolution. In this article, we highlight the genetic aspects surrounding AA with a particular focus on SMs and their clinical and pathophysiological implications in this disease. A discussion about the genetic causes of familial/constitutional aplastic anemia is outside the scope of this review.
| S O M ATI C M UTATI O N S
Sequencing to a significant depth using high-sensitivity polymerase chain reaction techniques can uncover low allele fractions and help identify AA cases harboring sub-clonal mutations associated with MDS and AML. 7 The mean allele burdens in AA are substantially lower, at around 10%, when compared to MDS. 4 Recent data from a whole-exome sequencing study suggest that mutations in AA carry signatures of immune escape and proliferative signaling. 
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Mutations in TET2 promote self-renewal of stem cells by providing them a proliferative advantage 18 whereas mutations in PIGA genes lead to functional loss of the HLA allele leading to immune escape of the defective clones. 19 Furthermore, the detection of SMs involving some of these genes such as DNMT3A, ASXL1, BCOR can risk stratify patients into high risk for development of late clonal disorders namely MDS and AML. 3, 4, 9 Temporal pattern profiles of clonal dynamics differ by the specific mutation involved; clones harboring mutations in PIGA and BCOR/BCORL1 tend to diminish or retain stable in size over time whereas clones carrying DNMT3A and ASXL1 mutations typically grow in size with time. 4 A comparison of mutational profiles between AA and MDS suggests that although most of the clonal events during the course of AA do not initiate MDS, somatic ancestral mutation events in specific genes can predispose to secondary development of MDS. 20 The early detection of the deleterious clones argues for consideration for stem cell transplantation in favor of IST due to the very high risk of disease transformation. In this regard, it is important to note that SMs in AA are typically detected at a low variant allele frequency (VAF) level. The correlation of VAF with disease outcomes has potential clinical implications on disease trajectory prediction and prospective treatment decision making and warrants further investigation. This can however be challenging based on the limited data suggesting that increasing sizes of deleterious clones do not necessarily herald MDS/AML progression. 4 Similar to the case with cytogenetic chromosomal abnormalities, clones characterized by mutational events may only appear transiently before being diluted by re-expansion of normal HSC pool during the process of bone marrow recovery. 4, 15 These data suggest that the clonal dynamics are highly variable and complex, and not necessarily determinative.
In addition to HSCs, cytotoxic T cells may also accumulate acquired mutations in genes that regulate survival and immunity during the process of proliferation. TheSTAT3 gene is mutated in 40% of cases with T-large granular lymphocytic (T-LGL) leukemia and helps identify this disorder in patients with unexplained cytopenias. 21 However, STAT3 mutations may be present in a small proportion of AA and are associated with better responses to IST.
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Eltrombopag (E-PAG) is a synthetic TPO-mimetic that binds to and activates the thrombopoetin receptor (TPO) present on stem progenitor cells and megakaryocytes. Eltrombopag was initially studied in the refractory setting where it was shown to be effective in producing trilineage hematopoiesis. 23, 24 Based on its promising activity in the relapse setting, the drug has also been explored in the frontline setting in conjunction with IST. 25, 26 Of the 88 patients enrolled in the study by Townsley et al, 26 cytogenetic abnormalities had occurred in seven patients. The investigators concluded that clonal evolution to MDS occurred at a similar frequency compared to their historic experience with standard IST. Preliminary NGS data suggest that occasional expansion of clones with potentially leukemogenic mutations is observed during treatment with E-PAG. 27 However, the rates of myeloid-associated SMs and of cytogenetic evolution in patients treated with IST with E-PAG do not appear to be higher than is reported in AA treated with IST alone suggesting that the addition of E-PAG to IST may not be associated with a higher risk of clonal progression. The presence of clonality in AA is best exemplified by the detection of PNH clones identified by flow cytometry. An associated PNH clone is found in up to 70% of patients with aplastic anemia. 30, 31 These PNH clones may remain stable, decrease in size, or expand and progress to clinical PNH particularly if patients do not respond to immunosuppressive therapy. 32, 33 The PNH clonal population is characterized by glycophosphatidyl inositol (GPI)-deficient anchor due to somatic loss-of-function mutations in the X-linked PIGA gene. 
| IMMUNOG ENE TIC S OF IMMUNE DYS REG UL ATION
The existing data support the influence of HLA polymorphisms on disease pathophysiology. Ethnic differences in genetic predisposition to AA risk appear to be shaped by HLA allele variations although it is difficult to draw definitive conclusions from specific ethnic group observations due to differences in the linkage disequilibrium existing between HLA alleles in different populations. Specific HLA allelotypes have been associated with the presence of PNH clones, 41, 42 increased [43] [44] [45] [46] or decreased 44, 47 susceptibility to developing AA, and some others with response to IST. 41, 44 The underlying pathophysiologic mechanism appears to be an induction of immune attack by activation of autoreactive cytototoxic T-cell clonotypes against
HSCs in a HLA-restricted pattern. 48 Recent focus has also been on the impact of somatic acquired mutations in the HLA class genes on AA-related autoimmunity. In a study by Babushok et al, 49 66 candidates with AA were screened for somaticHLA class 1 loss, of whom 11 (17%) were found to have Other mechanisms of MHC class I loss include mutations in beta-2-microglobulin, 7 a component of the MHC class I complex that is essential for MHC class I surface expression and CD8 T-cell function. 56 The recognition of normal HLA class I molecules on target cells downregulates NK cytotoxicity, and these MHC-1-deficient HSCs may thus be targets for NK cytotoxicity. 57 The mechanisms of immune escape of these HSCs from NK cells remain to be fully un- 
| THE T-CELL REPERTOIRE
The role of CD8+ T cells is best characterized among the T lymphocyte subsets. CD8+ T cells are increased in the bone marrow in AA and seem to be recruited by chemotactic signals such as by CXC3 receptor 1. 60 These CD8+ T cells are skewed toward oligoclonal patterns with highly restricted V-beta chain sequences supporting an antigen-driven expansion. 61, 62 Further, a systematic analysis of the complementarity determining region-3 T-cell receptor (TCR)
repertoire in patients with AA demonstrated a homology >98% between individuals, supporting a public immune response in disease pathology. 62 The presence, disappearance, and return of the highly skewed immune-dominant T-cell clonotypes also help predict, follow responses to, and detect relapse, respectively, after IST.
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The putative auto-antigens against which these T cells react are Similarly, del(13q) clones are found to expand following ISTs sug-
gesting a yet-to-be-delineated immune escape. 72 Both trisomy 8 and 
